A study looking at the feasibility of using repeated sampling of validated digital measures at home, in patients with early-stage Alzheimer’s Disease (AD), has completed enrollment for a multi-site study.
A company focusing on developing fibrin-targeted therapies to treat inflammatory neurodegenerative and retinal diseases announced the initiation of dosing for its lead asset THN391Monday (May 15) .
Cumulus Neuroscience has been given the clearance by the US Food and Drug Administration (FDA) and the company says this will accelerate treatments for neuropsychiatric and neurodegenerative disorders.
On Friday (Jan 6), the US Food and Drink Administration (FDA) granted a licence for another anti-amyloid drug – lecanemab – to treat Alzheimer’s disease.
Clinical data findings from Actinogen’s Phase 2a study measuring the effects of Xanamem in patients with biomarker-positive Alzheimer’s Disease validated company’s ongoing program.
The pharmaceutical company has inked a strategic collaboration with the drug discovery firm, centering on uncovering novel targets in Alzheimer’s disease.
After scientists and reporters raised red flags about a study, Cassava Sciences is being accused of falsifying data in pursuit of an Alzheimer’s treatment.
A leader from the health tech company explains how voice-based technologies could transform monitoring of patients with dementia, Alzheimer’s, and other conditions.
The biomarker developer is partnering with Alzheimer Center Amsterdam on decentralized assessment of patient cognition and function in preclinical research.
Biogen releases further details on how its Phase 4 post-marketing confirmatory study for Alzheimer’s drug, Aduhelm, will run: including increased enrolment and enhanced efforts to encourage diversity.
The digital therapeutics firm's Neuroglee Connect remote care platform and virtual clinic is for patients with mild cognitive impairment, including Alzheimer’s.
The National Institute on Aging has launched Outreach Pro, an online tool aimed to help connect with underrepresented populations for Alzheimer’s trials.
The health data specialist and pharma firm are partnering on solutions around remote collection of digital data for detection and monitoring of treatments.
Eli Lilly and Company and Banner Alzheimer’s Institute have announced a strategic research collaboration as part of the planned Phase 3 study for donanemab in participants at risk from cognitive and functional decline related to Alzheimer’s disease.
Acting US FDA commissioner, Janet Woodcock, has called for an independent federal review of interactions between officials at her agency and representatives of Biogen, prior to the recent approval of the pharma company’s treatment for Alzheimer’s disease....
The current COO will assume leadership of the neuro-focused pharma firm while the company board investigates questions on Leen Kawas’s doctoral research.
The US Food and Drug Administration (FDA) has approved Biogen’s Aduhelm (aducanumab) for the treatment of Alzheimer’s: making it the first new treatment approved for the disease since 2003.
The CRO has opened a new clinic in response to demand for early-stage research, specifically for Alzheimer’s Disease, and expanded its footprint in India to conduct studies ‘at favorable pricing with faster timelines,’ say company executives.
Computer model predicts worsening cognitive scores, opening door to the use of machine learning in the selection of participants in Alzheimer’s disease trials.
PPD’s patient access business unit AES will support clinical trial enrollment of participants in the Synexus HealthyMinds Registry, which aims to register 30,000 adults for a five-year study.
Datacubed Health’s mobile platform has been selected to support a longitudinal Alzheimer’s study aimed at better understanding the disease and finding effective treatments.
Large clinical trials can be particularly useful in the early treatment and prevention of neurodegenerative diseases because of the amount of data collected, though patient recruitment and retention are challenging, says biostatistician.
Eli Lilly and Company and AC Immune have signed an agreement for the research and development of tau aggregation inhibitor small molecules, and AC Immune signed a strategic partnership with WuXi biologics.
Advanced Clinical is partnering with Cognitive Clinical Trials to overcome recruitment road blocks in Alzheimer’s clinical trials and expedite research through patient centric model.
Previous setbacks in Alzheimer’s disease research for disease-modifying treatments have set the stage for a pipeline of new medicines now moving into clinical trials, according to a recent PhRMA report.
A study at Washington University in St. Louis has shown a new way to deliver drugs to the brainstem in a non-invasive administration: microbubbles and ultrasound.
The multi-year project with an unnamed pharmaceutical company will use the macaque monkey as a developmental model for progressive brain disorders and is valued at more than $1m.
Synexus is looking to register 30,000 adults for a five-year study with the goal of identifying potential prevention methods and possible treatments for Alzheimer’s disease and other dementias.
While senior citizens consume roughly one third of all medications – and make up only 13% of the population – factors that complicate geriatric clinical trials leave gaps in knowledge and developments.
At least 50,000 volunteers are needed to participate in clinical trials for Alzheimer’s disease – the global cost of which is expected to reach $2 trillion by 2030.
In an exclusive licensing agreement with Merck & Co Inc (MSD), Cerveau will take on development of the firm’s investigative PET imaging agent up to Phase III trials for Alzheimer’s Disease.
A transdermal patch formulation of the most commonly used Alzheimer's disease (AD) drug could be on the market in 2019 - two to three years earlier than expected.
Merz is hoping to further its Alzheimer’s research by licensing DiaGenic’s biomarkers for a transitional stage of disease, which is “very important” for stratification of clinical trials.
Peptide Technologies showcased their latest rapid automated peptide
synthesis equipment at Pittcon 2008, including a new product, the
benchtop Tribute instrument.
Scientists have discovered that a protein called cystatin C can
prevent damaging Alzheimer's plaques from forming by keeping their
constituent protein water soluble.
The UK's largest charity, the Wellcome Trust, has awarded £1.3m
(€1.9m) to fund the world's largest ever genome-wide association
study to identify the genetic origins of Alzheimer's disease.
UK researchers have published results linking the beta amyloid
protein associated with Alzheimer's disease to glaucoma, opening up
a much needed new target for glaucoma therapies.
